ABCL · AbCellera Biologics Inc.
$11.38
+0.41 (+3.74%)
At close · Aug 14
Market Cap
$3.49B
Shares
306.61M
AbCellera Biologics Inc. Earnings Call Transcripts
Every quarterly earnings call for AbCellera Biologics Inc. (ABCL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1740.6%
$101.38M
$26.62M
'22 Q3
22-11-08
▼84.5%
$21.54M
−$29.89M
'22 Q4
23-02-21
▼96.1%
$12.19M
−$40.11M
'23 Q1
23-05-04
▼78.1%
$10.06M
−$30.53M
'23 Q2
23-08-03
▼93.5%
$6.60M
−$28.61M
'23 Q3
23-11-02
▼57.4%
$9.18M
−$47.15M
'23 Q4
24-02-20
▼18.4%
$9.95M
−$40.61M
'24 Q1
24-05-07
▼27.2%
$7.32M
−$36.93M
'24 Q2
24-08-06
▼1.4%
$6.51M
−$51.11M
'24 Q3
24-11-04
▼45%
$5.05M
−$34.21M
'24 Q4
25-02-27
▼57.5%
$4.24M
−$45.62M
'25 Q1
25-05-08
▲133.3%
$17.08M
−$34.73M
'25 Q2
25-08-07
▲37.6%
$8.96M
−$57.12M
'25 Q3
25-11-06
▲788.4%
$44.85M
−$8.95M
'25 Q4
26-02-24
▲96.3%
$8.31M
−$43.16M
'26 Q1
26-05-11
LATEST
▼76.3%
$4.05M
−$55.43M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Q2 2026 Earnings Results and Business Update
Positive tone
Business development deals (Vertex, Jazz, AbbVie)
T-cell engagement (TCE) platform and partnerships
ABCL635 Phase 2 in VMS/menopause
Revenue
$4.05M
▼ 76.3% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-11
AbCellera Biologics Inc. Q1 FY2026 Earnings Call
Revenue
$8.31M
▲ 96.3% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-21
2026 Bloom Burton & Co. Healthcare Investor Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
AbCellera Biologics Inc. Q4 FY2025 Earnings Call
Confident tone
Pipeline expansion and development candidates
ABCL635 Phase II readout
Liquidity and financial position
Revenue
$44.85M*
▲ 788.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
AbCellera Biologics Inc. Q3 FY2025 Earnings Call
Positive tone
Clinical pipeline progress
Liquidity and financial position
Partner-initiated programs
Revenue
$8.96M
▲ 37.6% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
AbCellera Biologics Inc. Q2 FY2025 Earnings Call
Confident tone
ABCL635 vasomotor symptoms program
ABCL575 atopic dermatitis program
Pipeline expansion and ABCL688
Revenue
$17.08M
▲ 133.3% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
AbCellera Biologics Inc. Q1 FY2025 Earnings Call
Positive tone
ABCL635 program (NK3R antibody for menopausal VMS)
Clinical milestones and timing
Differentiation vs. small molecule NK3R antagonists
Revenue
$4.24M
▼ 57.5% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
AbCellera Biologics Inc. Q4 FY2024 Earnings Call
Positive tone
Facilities and platform investments
Lead programs ABCL635 and ABCL575
Reduced partnership activity
Revenue
$5.05M*
▼ 45% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
AbCellera Biologics Inc. Q3 FY2024 Earnings Call
Positive tone
Liquidity and cash runway
Platform and facility build-out
Partnering strategy shift to co-development
Revenue
$6.51M
▼ 1.4% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
AbCellera Biologics Inc. Q2 FY2024 Earnings Call
Positive tone
TCE platform programs
Strategic partnerships and business development
Revenue and financial trends
Revenue
$7.32M
▼ 27.2% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
AbCellera Biologics Inc. Q1 FY2024 Earnings Call
Positive tone
TCE platform and technology
Strategic partnerships and deal-making
Internal pipeline advancement
Revenue
$9.95M
▼ 18.4% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
AbCellera Biologics Inc. Q4 FY2023 Earnings Call
Confident tone
Internal programs ABCL635 and ABCL575 progress
Manufacturing build-out and forward integration
Partnerships and royalty portfolio
Revenue
$9.18M*
▼ 57.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
AbCellera Biologics Inc. Q3 FY2023 Earnings Call
Revenue
$6.60M
▼ 93.5% YoY Diluted EPS
$-0.10
▼ 225% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
AbCellera Biologics Inc. Q2 FY2023 Earnings Call
Revenue
$10.06M
▼ 78.1% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
AbCellera Biologics Inc. Q1 FY2023 Earnings Call
Revenue
$12.19M
▼ 96.1% YoY Diluted EPS
$-0.14
▼ 125.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
AbCellera Biologics Inc. Q4 FY2022 Earnings Call
Revenue
$21.54M*
▼ 84.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
AbCellera Biologics Inc. Q3 FY2022 Earnings Call
Revenue
$101.38M
▲ 1740.6% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
AbCellera Biologics Inc. Q2 FY2022 Earnings Call
Revenue
$45.92M
▲ 66.1% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
AbCellera Biologics Inc. Q1 FY2022 Earnings Call
Revenue
$316.58M
▲ 56.2% YoY Diluted EPS
$0.54
▲ 45.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
AbCellera Biologics Inc. Q4 FY2021 Earnings Call
Revenue
$139.31M*
▼ 33% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
AbCellera Biologics Inc. Q3 FY2021 Earnings Call
Revenue
$5.51M
▼ 41.2% YoY Diluted EPS
$-0.08
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
AbCellera Biologics Inc. Q2 FY2021 Earnings Call
Revenue
$27.64M
▲ 146.2% YoY Diluted EPS
$-0.01
▼ 133.3% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
AbCellera Biologics Inc. Q1 FY2021 Earnings Call
Revenue
$202.74M
▲ 4253.5% YoY Diluted EPS
$0.37
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-29
AbCellera Biologics Inc. Q4 FY2020 Earnings Call
Revenue
$207.91M*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls
Key facts
CIK
1703057
CUSIP
00288U106
13F (30d)
147 filings
145 filers
Visit website
Investor relations